Saturday, October 3, 2026
24.8 C
Bengaluru

Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy

In 1989, oncology in India was not a business unit. It was a scientific outpost.

I entered this field when we measured success by the depth of a clinical conversation, not the breadth of a CRM dashboard. Today, oncology is a multi-billion-dollar strategic chess match. But as we have gained scale, there is a lingering question: have we lost the plot?

Looking back at four decades from the frontlines, the evolution of cancer care in India was not a slow climb. It was a series of radical rewiring events that changed how we think, sell, and treat.

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

Why Is the World’s Pharmacy Failing to Protect Patients from Harm?

This MedicinMan Intelligence Report follows a disturbing trail—from Arun...

Shakul Srivastava has been appointed as Senior Vice President at Indian Immunologicals Limited.

With over three decades of experience in the pharmaceutical...

The Rx–Outcomes Dichotomy: India Has Iron Tablets. Why Does Anaemia Persist?

India’s anaemia challenge is not simply about access to...

10 Years of Pharma M&A — Who’s Really Benefited?

Pharmaceutical M&A is usually discussed in the language of...

What’s Killing Patients? Cancer or Rigged Drug Prices?

The disease is real. So is the markup. Confusing...

Topics

spot_img

Related Articles

spot_imgspot_img